What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database

Edouard-Jules Laforgue (1) , Marion Istvan (1) , Marylène Guerlais , Anicet Chaslerie , Pascal Artarit , Genevieve Vallot , Pascale Jolliet (1) , Marie Grall-Bronnec (1) , Caroline Victorri-Vigneau (1)

1 SPHERE - MethodS in Patients-centered outcomes and HEalth ResEarch

The inherent risk of agranulocytosis associated with clozapine requires the realization of weekly white blood cell monitoring (WBCM) during the 18 first weeks of treatment. The aim of this study was to assess the compliance with WBCM during clozapine initiation for schizophrenia and Parkinson's disease (PD) subjects.

Mots clés: Clozapine; Parkinson’s disease; health insurance database; schizoaffective disorder; schizophrenia

Domaines: Sciences du Vivant [q-bio]

Edouard-Jules Laforgue, Marion Istvan, Marylène Guerlais, Anicet Chaslerie, Pascal Artarit, et al.. What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database: A compliance analysis using the French health insurance database. Expert Opinion on Drug Safety, 2021, 20 (10), pp.1247-1256. ⟨10.1080/14740338.2021.1939304⟩. ⟨hal-03406940⟩